News
Public · Published
EW: PROGRESS supports earlier TAVR evaluation in at-risk moderate AS; CLASP IITR showed PASCAL health-status gains
The CLASP IITR trial met its six-month endpoint, with PASCAL benefits driven mainly by health status. The PROGRESS trial found lower two-year death or heart failure event risk with TAVR in at-risk moderate aortic stenosis, along with strong safety and fewer heart failure hospitalizations.
Published:
Updated:
What happened
The CLASP IITR trial met its six-month endpoint, with PASCAL benefits driven mainly by health status. The PROGRESS trial found lower two-year death or heart failure event risk with TAVR in at-risk moderate aortic stenosis, along with strong safety and fewer heart failure hospitalizations.
Confirmed
Global impact / market context
For Edwards Lifesciences, trial results supporting earlier TAVR use in moderate aortic stenosis could widen the patient group treated with these heart-valve procedures, supporting device revenue. The PASCAL findings reinforce its heart-valve repair portfolio by linking the device to better patient health status.
Analyst inference
These results shape investor expectations for Edwards' structural heart business, where TAVR sales are a key revenue driver. Evidence favoring earlier intervention may support adoption and capital spending by hospitals, while competitors in heart-valve devices face a shifting treatment standard.
Analyst inference
What to watch
- CLASP IITR met its six-month endpoint, with PASCAL benefits driven mainly by health status, a measure of how patients feel and function. Confirmed
- Watch for regulatory submissions or label expansion requests that would let TAVR be evaluated and used in at-risk moderate aortic stenosis patients. Proposed
- Track hospital adoption and capital spending on TAVR programs, since broader treatment of moderate aortic stenosis could raise procedure volumes and Edwards' device revenue. Analyst inference
Evidence
- Original source link unavailable